Intravenous iron plus erythropoietin versus erythropoietin alone for treatment of anaemia in patients of end stage renal disease

Abstract

Objective: To determine the efficacy of intravenous iron along with erythropoietin for treatment of anemia in patients of chronic kidney disease undergoing maintenance haemodialysis. Study Design: Randomized comparative prospective, unblinded study. Study Place: Divisional Headquarter Teaching Hospital Mirpur Azad Kashmir. Duration Of Study: 06 Months, from June 2021 to December 2021. Methodology: This study was conducted in Divisional Headquarter Teaching Hospital Mirpur AJK and it included 107 patients with metabolically stable chronic kidney disease with hemoglobin of 8-11 g/dl. Patients were randomly assigned into 2 groups,, ”EPO group” which received subcutaneous erythropoietin only with each hemodialysis session and the “Iron group” which received erythropoietin with each session of hemodialysis and 200mg of intravenous iron once a month with up or down titration every monthly according to hemoglobin and transfer in saturation level in serum. Standard CKD measurement was same in both groups. Serum hemoglobin and serum transferrin saturation was measured at the start of the treatment. Both groups were followed every monthly for efficacy and side effect profile and assessed at 3 months with serum hemoglobin and seum transferrin saturation level.